Needham & Company LLC Reaffirms “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report issued on Friday, Benzinga reports. They currently have a $9.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 79.28% from the company’s current price.

Separately, Truist Financial increased their price objective on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.16.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $5.02 on Friday. The stock has a 50 day moving average price of $6.04 and a 200 day moving average price of $5.03. Autolus Therapeutics has a one year low of $1.61 and a one year high of $7.45. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.22 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, analysts predict that Autolus Therapeutics will post -0.71 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD purchased a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $19,328,000. Perceptive Advisors LLC acquired a new stake in Autolus Therapeutics during the fourth quarter worth $11,793,000. Laurion Capital Management LP purchased a new stake in Autolus Therapeutics in the fourth quarter valued at $2,850,000. Alyeska Investment Group L.P. acquired a new position in shares of Autolus Therapeutics in the 4th quarter valued at $2,782,000. Finally, Lynx1 Capital Management LP acquired a new position in shares of Autolus Therapeutics in the 3rd quarter valued at $3,176,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.